Recruiting

Innate Immunity in Allergic Asthma

The purpose of this study is to determine whether a potential type 2 signature, obtained through stimulation of cell lines with various allergens in vitro, correlates with an allergic or asthmatic disease state ex vivo. This type 2 signature will be multi-hierarchical in nature and will be comprised cell surface receptor expression, pathway activation, and gene upregulation.

ClinicalTrials.gov IDNCT06068335

PhaseNot Applicable

Enrollment100

SponsorUniversity of Central Florida

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Asthma

About this study

Primary outcomes

To determine which parameters of the established type-2 signature obtained in vitro is significantly different between healthy controls, allergic individuals, and asthmatic individuals ex vivo. (1 year)

Eligibility information

Inclusion Criteria: * Participants must be at least 18 years of age * no history of allergic disease (healthy controls), have clinically diagnosed allergies, or have clinically diagnosed asthma. Exclusion Criteria: * Pregnant women and prisoners will be excluded from the study. * Individuals currently suffering from any acute infections and those known to suffer from light-headedness will be excluded.

Study locations

University of Central Florida, Orlando, Florida 32816 United States

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.